Assessment, by transcription-mediated amplification, of virologic responsein patients with chronic hepatitis C virus treated with peginterferon alpha-2a

Citation
C. Sarrazin et al., Assessment, by transcription-mediated amplification, of virologic responsein patients with chronic hepatitis C virus treated with peginterferon alpha-2a, J CLIN MICR, 39(8), 2001, pp. 2850-2855
Citations number
25
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Clinical Immunolgy & Infectious Disease",Microbiology
Journal title
JOURNAL OF CLINICAL MICROBIOLOGY
ISSN journal
0095-1137 → ACNP
Volume
39
Issue
8
Year of publication
2001
Pages
2850 - 2855
Database
ISI
SICI code
0095-1137(200108)39:8<2850:ABTAOV>2.0.ZU;2-J
Abstract
Transcription-mediated amplification (TMA) is an isothermal, autocatalytic target amplification method which has the potential to detect less than 50 hepatitis C virus (HCV) RNA copies/ml (10 IU/ml). The TMA assay was used to assess the presence of residual HCV RNA in plasma from patients treated wi th polyethylene glycol-modified interferon alpha -2a (peginterferon alpha - 2a) who showed a virologic relapse after the end of therapy. Stored end-of- treatment and end-of-follow-up plasma samples from 177 of 267 patients trea ted with peginterferon alpha -2a (S. Zeuzem et al., N. Engl. J. Med. 343:16 66-1672, 2000) were available for retesting by TMA. Plasma samples from pat ients in the same study who exhibited virologic relapse after treatment wit h standard interferon alpha -2a served as controls. Virologic response duri ng the trial was defined as HCV RNA that was undetectable using a PCR-based test system with a sensitivity of 50 IU/mL (Cobas Amplicor HCV version 2.0 ) and was compared with TMA-based retesting results (VERSANT HCV RNA Qualit ative Assay). Residual HCV RNA was detected in 4 of 60 cases (7%) by the TM A technology in end-of-treatment plasma samples from patients who relapsed after receiving peginterferon alpha -2a and in 6 of 18 patients (33%) follo wing therapy with standard interferon alpha -2a. For peginterferon alpha -2 a-treated patients with sustained virologic response, HCV RNA was detectabl e by TMA in end-of-treatment samples in 3 of 78 cases but in none of the en d-of-follow-up samples. For all end-of-treatment and end-of-follow-up plasm a samples of virologic nonresponders, a complete concordance between the PC R-based assay and TMA was observed. In conclusion, in patients with virolog ic relapse after the end of therapy, according to PCR, who were treated wit h peginterferon alpha -2a or standard interferon alpha -2a, residual HCV RN A was detectable in end-of-treatment samples by the TMA-based assay in 7 or 33% of cases, respectively. The lower rate of residual HCV RNA detection b y TMA for patients treated with peginterferon alpha -2a than that for patie nts treated with standard interferon alpha -2a may be due to the maintained antiviral pressure of the long-acting peginterferon alpha -2a at the end-o f-treatment visit.